StockData
Edgewise Therapeutics, Inc. logo

Edgewise Therapeutics, Inc. (EWTX) stock

EWTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/30
$41.37−0.67 (-1.59%)

Close on Nov 18, 2026Market cap $4.49BP/E –Yield –

Edgewise Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Edgewise Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$218.90M. For fiscal 2025 it was -$191.41M. The highest annual figure on record is -$17.19M in fiscal 2020.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$191.41M–
FY2024Dec 31, 2024-$158.83M–
FY2023Dec 31, 2023-$114.36M–
FY2022Dec 31, 2022-$71.66M–
FY2021Dec 31, 2021-$43.22M–
FY2020Dec 31, 2020-$17.19M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$61.94M–
Q1 FY2026Mar 31, 2026-$54.12M–
Q4 FY2025Dec 31, 2025-$55.98M–
Q3 FY2025Sep 30, 2025-$46.86M–
Q2 FY2025Jun 30, 2025-$42.61M–
Q1 FY2025Mar 31, 2025-$45.96M–
Q4 FY2024Dec 31, 2024-$45.54M–
Q3 FY2024Sep 30, 2024-$40.43M–
Q2 FY2024Jun 30, 2024-$38.11M–
Q1 FY2024Mar 31, 2024-$34.75M–
Q4 FY2023Dec 31, 2023-$33.86M–
Q3 FY2023Sep 30, 2023-$29.45M–
Q2 FY2023Jun 30, 2023-$25.34M–
Q1 FY2023Mar 31, 2023-$25.70M–
Q4 FY2022Dec 31, 2022-$22.08M–
Q3 FY2022Sep 30, 2022-$18.26M–
Q2 FY2022Jun 30, 2022-$16.49M–
Q1 FY2022Mar 31, 2022-$14.83M–
Q4 FY2021Dec 31, 2021-$12.82M–
Q3 FY2021Sep 30, 2021-$13.08M–
Q2 FY2021Jun 30, 2021-$10.46M–
Q1 FY2021Mar 31, 2021-$6.86M–
Q4 FY2020Dec 31, 2020-$6.34M–
Q3 FY2020Sep 30, 2020-$3.64M–
Q2 FY2020Jun 30, 2020-$3.96M–
Q1 FY2020Mar 31, 2020-$3.25M–

More Edgewise Therapeutics figures

See a number that looks wrong?